Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Synthesis and physicochemical characterization of (6S)-5-formiminotetrahydrofolate; a reference standard for metabolomics.

Lewin AH, Silinski P, Zhong D, Gilbert A, Mascarella SW, Seltzman HH.

Org Biomol Chem. 2018 Aug 8;16(31):5684-5690. doi: 10.1039/c8ob00245b.

PMID:
30046777
2.

Synthetic peripherally-restricted cannabinoid suppresses chemotherapy-induced peripheral neuropathy pain symptoms by CB1 receptor activation.

Mulpuri Y, Marty VN, Munier JJ, Mackie K, Schmidt BL, Seltzman HH, Spigelman I.

Neuropharmacology. 2018 Sep 1;139:85-97. doi: 10.1016/j.neuropharm.2018.07.002. Epub 2018 Jul 5.

3.

Synthesis of 13 C-labeled 5-aminoimidazole-4-carboxamide-1-β-D-[13 C5 ] ribofuranosyl 5'-monophosphate.

Zarkin AK, Elkins PD, Gilbert A, Jester TL, Seltzman HH.

J Labelled Comp Radiopharm. 2018 Sep;61(11):820-825. doi: 10.1002/jlcr.3647. Epub 2018 Jul 15.

PMID:
29902835
4.

Peripherally restricted cannabinoid 1 receptor agonist as a novel analgesic in cancer-induced bone pain.

Zhang H, Lund DM, Ciccone HA, Staatz WD, Ibrahim MM, Largent-Milnes TM, Seltzman HH, Spigelman I, Vanderah TW.

Pain. 2018 Sep;159(9):1814-1823. doi: 10.1097/j.pain.0000000000001278.

5.

Synthesis and Physicochemical Characterization of the One-Carbon Carrier 10-Formyltetrahydrofolate; A Reference Standard for Metabolomics.

Lewin AH, Silinski P, Hayes J, Gilbert A, Mascarella SW, Seltzman HH.

Metabolomics. 2017 Oct;13(10). pii: 117. doi: 10.1007/s11306-017-1256-1. Epub 2017 Aug 31.

6.

Caged Naloxone: Synthesis, Characterization, and Stability of 3- O-(4,5-Dimethoxy-2-nitrophenyl)carboxymethyl Naloxone (CNV-NLX).

Lewin AH, Fix SE, Zhong D, Mayer LD, Burgess JP, Mascarella SW, Reddy PA, Seltzman HH, Carroll FI.

ACS Chem Neurosci. 2018 Mar 21;9(3):563-567. doi: 10.1021/acschemneuro.7b00378. Epub 2017 Dec 8.

PMID:
29154536
7.

Metabolic Profiling of CB1 Neutral Antagonists.

Seltzman HH, Maitra R, Bortoff K, Henson J, Reggio PH, Wesley D, Tam J.

Methods Enzymol. 2017;593:199-215. doi: 10.1016/bs.mie.2017.06.025. Epub 2017 Jul 10.

8.

Peripherally Selective Cannabinoid 1 Receptor (CB1R) Agonists for the Treatment of Neuropathic Pain.

Seltzman HH, Shiner C, Hirt EE, Gilliam AF, Thomas BF, Maitra R, Snyder R, Black SL, Patel PR, Mulpuri Y, Spigelman I.

J Med Chem. 2016 Aug 25;59(16):7525-43. doi: 10.1021/acs.jmedchem.6b00516. Epub 2016 Aug 10.

9.

Novel Synthesis and Pharmacological Characterization of NOP Receptor Agonist 8-[(1S,3aS)-2,3,3a,4,5,6-Hexahydro-1H-phenalen-1-yl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one (Ro 64-6198).

Chang SD, Brieaddy LE, Harvey JD, Lewin AH, Mascarella SW, Seltzman HH, Reddy PA, Decker AM, McElhinny CJ Jr, Zhong D, Peterson EE, Navarro HA, Bruchas MR, Carroll FI.

ACS Chem Neurosci. 2015 Dec 16;6(12):1956-64. doi: 10.1021/acschemneuro.5b00208. Epub 2015 Sep 30.

10.

Allosteric modulation of a cannabinoid G protein-coupled receptor: binding site elucidation and relationship to G protein signaling.

Shore DM, Baillie GL, Hurst DH, Navas F 3rd, Seltzman HH, Marcu JP, Abood ME, Ross RA, Reggio PH.

J Biol Chem. 2014 Feb 28;289(9):5828-45. doi: 10.1074/jbc.M113.478495. Epub 2013 Dec 23.

11.

Identification of the GPR55 antagonist binding site using a novel set of high-potency GPR55 selective ligands.

Kotsikorou E, Sharir H, Shore DM, Hurst DP, Lynch DL, Madrigal KE, Heynen-Genel S, Milan LB, Chung TD, Seltzman HH, Bai Y, Caron MG, Barak LS, Croatt MP, Abood ME, Reggio PH.

Biochemistry. 2013 Dec 31;52(52):9456-69. doi: 10.1021/bi4008885. Epub 2013 Dec 17.

12.

Emergence and properties of spice and bath salts: a medicinal chemistry perspective.

Lewin AH, Seltzman HH, Carroll FI, Mascarella SW, Reddy PA.

Life Sci. 2014 Feb 27;97(1):9-19. doi: 10.1016/j.lfs.2013.09.026. Epub 2013 Oct 7. Review.

PMID:
24113072
13.

The importance of hydrogen bonding and aromatic stacking to the affinity and efficacy of cannabinoid receptor CB2 antagonist, 5-(4-chloro-3-methylphenyl)-1-[(4-methylphenyl)methyl]-N-[(1S,2S,4R)-1,3,3-trimethylbicyclo[2.2.1]hept-2-yl]-1H-pyrazole-3-carboxamide (SR144528).

Kotsikorou E, Navas F 3rd, Roche MJ, Gilliam AF, Thomas BF, Seltzman HH, Kumar P, Song ZH, Hurst DP, Lynch DL, Reggio PH.

J Med Chem. 2013 Sep 12;56(17):6593-612. doi: 10.1021/jm400070u. Epub 2013 Aug 14.

14.

Designer drugs: a medicinal chemistry perspective.

Carroll FI, Lewin AH, Mascarella SW, Seltzman HH, Reddy PA.

Ann N Y Acad Sci. 2012 Feb;1248:18-38. doi: 10.1111/j.1749-6632.2011.06199.x. Epub 2011 Nov 17. Review.

PMID:
22092008
15.

Identification of the GPR55 agonist binding site using a novel set of high-potency GPR55 selective ligands.

Kotsikorou E, Madrigal KE, Hurst DP, Sharir H, Lynch DL, Heynen-Genel S, Milan LB, Chung TD, Seltzman HH, Bai Y, Caron MG, Barak L, Abood ME, Reggio PH.

Biochemistry. 2011 Jun 28;50(25):5633-47. doi: 10.1021/bi200010k. Epub 2011 Jun 1.

16.

Synthesis and biological evaluation of bivalent ligands for the cannabinoid 1 receptor.

Zhang Y, Gilliam A, Maitra R, Damaj MI, Tajuba JM, Seltzman HH, Thomas BF.

J Med Chem. 2010 Oct 14;53(19):7048-60. doi: 10.1021/jm1006676.

17.

Targeting of the orphan receptor GPR35 by pamoic acid: a potent activator of extracellular signal-regulated kinase and β-arrestin2 with antinociceptive activity.

Zhao P, Sharir H, Kapur A, Cowan A, Geller EB, Adler MW, Seltzman HH, Reggio PH, Heynen-Genel S, Sauer M, Chung TD, Bai Y, Chen W, Caron MG, Barak LS, Abood ME.

Mol Pharmacol. 2010 Oct;78(4):560-8. doi: 10.1124/mol.110.066746. Epub 2010 Jul 22.

18.

Kappa opioid mediation of cannabinoid effects of the potent hallucinogen, salvinorin A, in rodents.

Walentiny DM, Vann RE, Warner JA, King LS, Seltzman HH, Navarro HA, Twine CE Jr, Thomas BF, Gilliam AF, Gilmour BP, Carroll FI, Wiley JL.

Psychopharmacology (Berl). 2010 Jun;210(2):275-84. doi: 10.1007/s00213-010-1827-6. Epub 2010 Mar 31.

19.

Synthesis and evaluation of Apogossypol atropisomers as potential Bcl-xL antagonists.

Wei J, Rega MF, Kitada S, Yuan H, Zhai D, Risbood P, Seltzman HH, Twine CE, Reed JC, Pellecchia M.

Cancer Lett. 2009 Jan 8;273(1):107-13. doi: 10.1016/j.canlet.2008.07.031. Epub 2008 Sep 7.

20.

Conformationally constrained analogues of N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4- dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716): design, synthesis, computational analysis, and biological evaluations.

Zhang Y, Burgess JP, Brackeen M, Gilliam A, Mascarella SW, Page K, Seltzman HH, Thomas BF.

J Med Chem. 2008 Jun 26;51(12):3526-39. doi: 10.1021/jm8000778.

PMID:
18512901
21.

Inhibition of milk ingestion and growth after administration of a neutral cannabinoid CB1 receptor antagonist on the first postnatal day in the mouse.

Fride E, Braun H, Matan H, Steinberg S, Reggio PH, Seltzman HH.

Pediatr Res. 2007 Nov;62(5):533-6.

PMID:
17805201
22.
23.
24.

Preparation of monoclonal antibodies reactive to the endogenous small molecule, anandamide.

Basta PV, Adcock AF, Tallent CR, Fleming DN, Seltzman HH, Whisnant CC, Cook CE.

J Immunol Methods. 2004 Feb 15;285(2):181-95.

PMID:
14980433
25.

N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor.

Hurst DP, Lynch DL, Barnett-Norris J, Hyatt SM, Seltzman HH, Zhong M, Song ZH, Nie J, Lewis D, Reggio PH.

Mol Pharmacol. 2002 Dec;62(6):1274-87.

PMID:
12435794
26.
27.

Structure and receptor activity for classical cannabinoids.

Seltzman HH.

Curr Med Chem. 1999 Aug;6(8):685-704. Review.

PMID:
10469886
28.

The bioactive conformation of aminoalkylindoles at the cannabinoid CB1 and CB2 receptors: insights gained from (E)- and (Z)-naphthylidene indenes.

Reggio PH, Basu-Dutt S, Barnett-Norris J, Castro MT, Hurst DP, Seltzman HH, Roche MJ, Gilliam AF, Thomas BF, Stevenson LA, Pertwee RG, Abood ME.

J Med Chem. 1998 Dec 17;41(26):5177-87.

PMID:
9857088
29.

Comparative receptor binding analyses of cannabinoid agonists and antagonists.

Thomas BF, Gilliam AF, Burch DF, Roche MJ, Seltzman HH.

J Pharmacol Exp Ther. 1998 Apr;285(1):285-92.

PMID:
9536023
30.

Synthesis and pharmacological comparison of dimethylheptyl and pentyl analogs of anandamide.

Seltzman HH, Fleming DN, Thomas BF, Gilliam AF, McCallion DS, Pertwee RG, Compton DR, Martin BR.

J Med Chem. 1997 Oct 24;40(22):3626-34.

PMID:
9357529
31.

Importance of the C-1 substituent in classical cannabinoids to CB2 receptor selectivity: synthesis and characterization of a series of O,2-propano-delta 8-tetrahydrocannabinol analogs.

Reggio PH, Wang T, Brown AE, Fleming DN, Seltzman HH, Griffin G, Pertwee RG, Compton DR, Abood ME, Martin BR.

J Med Chem. 1997 Sep 26;40(20):3312-8.

PMID:
9379452
32.

Synthesis and in vivo studies of a selective ligand for the dopamine transporter: 3 beta-(4-[125I]iodophenyl) tropan-2 beta-carboxylic acid isopropyl ester ([125I]RTI-121).

Lever JR, Scheffel U, Stathis M, Seltzman HH, Wyrick CD, Abraham P, Parham K, Thomas BF, Boja JW, Kuhar MJ, Carroll FI.

Nucl Med Biol. 1996 Apr;23(3):277-84.

PMID:
8782237
33.

Mapping dopamine transporters in the human brain with novel selective cocaine analog [125I]RTI-121.

Staley JK, Boja JW, Carroll FI, Seltzman HH, Wyrick CD, Lewin AH, Abraham P, Mash DC.

Synapse. 1995 Dec;21(4):364-72.

PMID:
8869167
34.

Selective labeling of the dopamine transporter by the high affinity ligand 3 beta-(4-[125I]iodophenyl)tropane-2 beta-carboxylic acid isopropyl ester.

Boja JW, Cadet JL, Kopajtic TA, Lever J, Seltzman HH, Wyrick CD, Lewin AH, Abraham P, Carroll FI.

Mol Pharmacol. 1995 Apr;47(4):779-86.

PMID:
7723739
35.

The design, synthesis and testing of desoxy-CBD: further evidence for a region of steric interference at the cannabinoid receptor.

Reggio PH, Bramblett RD, Yuknavich H, Seltzman HH, Fleming DN, Fernando SR, Stevenson LA, Pertwee RG.

Life Sci. 1995;56(23-24):2025-32.

PMID:
7776828
36.

A rational search for the separation of psychoactivity and analgesia in cannabinoids.

Reggio PH, McGaughey GB, Odear DF, Seltzman HH, Compton DR, Martin BR.

Pharmacol Biochem Behav. 1991 Nov;40(3):479-86.

PMID:
1806940
37.

Investigation of the role of the phenolic hydroxyl in cannabinoid activity.

Reggio PH, Seltzman HH, Compton DR, Prescott WR Jr, Martin BR.

Mol Pharmacol. 1990 Dec;38(6):854-62.

PMID:
2174506
38.

High-affinity cannabinoid binding sites in brain membranes labeled with [3H]-5'-trimethylammonium delta 8-tetrahydrocannabinol.

Nye JS, Seltzman HH, Pitt CG, Snyder SH.

J Pharmacol Exp Ther. 1985 Sep;234(3):784-91.

PMID:
2993595
39.

Radioimmunoassays for cannabinoids.

Cook CE, Seltzman HH, Schindler VH, Tallent CR, Chin KM, Pitt CG.

NIDA Res Monogr. 1982;42:19-32.

PMID:
6294523
40.

The interaction of mutagenic and carcinogenic agents with nucleic acids.

Van Duuren BL, Goldschmidt BM, Seltzman HH.

Ann N Y Acad Sci. 1969 Jan 27;153(3):744-57. No abstract available.

PMID:
5259547

Supplemental Content

Loading ...
Support Center